Failed primary on cUHDRS; subgroup analyses suggested benefit in patients not on anti-dopaminergic background therapy.
Details
- nct_id
- NCT04556656
- phase
- phase_3
- status
- completed
- domain
- huntingtons
- indication
- Manifest Huntington's Disease
- intervention
- Pridopidine 45mg BID (sigma-1 receptor agonist)
- sponsor
- Prilenia Therapeutics
- n_enrolled
- 499
- primary_endpoint
- cUHDRS at 65 weeks
Raw fields (1)
- metadata
{}